Technology offer : Peptides for serologic diagnostic of Ebola virus.

Technology's description

The Ebola virus is a member of the Filoviridae family; the virus is a highly virulent pathogen for humans and causes an acute, serious illness which is often fatal if untreated. Mortality rates of this hemorrhagic fever reach between 50% and 90%.
Recently the Ebola virus became an international public health concern due to outbreaks in West Africa and the World Health Organization is well involved in the management of this crisis.

Due to similar symptoms it can be difficult to distinguish Ebola virus from other infectious diseases such as malaria, typhoid fever and meningitis. Currently most of diagnostics need to be performed in biosafety level 4 laboratories, but in crisis situation there is an urgent need for rapid diagnostics adapted to the field.
Researchers from the IRD experts in Ebola virus identified few proteins of the virus directly involved in the human immune response. From these proteins, few small peptides have been successfully selected for a use in serologic diagnostics in ELISA. Our goal is now to develop from those peptides a lateral flow test for a rapid serological diagnostic adapted to the field.
We are looking for partnerships and collaboration with future license agreement.

Those peptides as they react with the immune system of survivors of Ebola outbreaks could also have an interest for a future vaccine development against the Ebola virus.



Advantages

  • Quick diagnostic
  • Easy to perform
  • Adapted to the field
  • Research team expert in Ebola virus, present on field in Gabon
Ref : OT-00051

Area of activity : HEALTH COSMETOLOGY

Download pdf

Industrial applications

  • Diagnostic of Ebola virus (ELISA, lateral flow) Vaccine against Ebola virus

Intellectual property

  • Patent field

Technology transfer

  • Co-development with licensing agreement

CONTACT


Vanessa ZEPPONI
Business developer

vanessa.zepponi@cvt-sud.fr
P: +33 (0)4 91 99 94 27